

# PRIOR AUTHORIZATION CRITERIA

**BRAND NAME**  
(generic)

**DARAPRIM**  
(pyrimethamine)

**Status: CVS Caremark Criteria**  
**Type: Initial Prior Authorization**

## Policy

### FDA-APPROVED INDICATIONS

#### Treatment of Toxoplasmosis

Daraprim is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.

#### Compendial Uses

Toxoplasmosis; Prophylaxis<sup>2,3,4,5</sup>

Pneumocystis jiroveci pneumonia; Prophylaxis<sup>2,3,4</sup>

Cystoisosporiasis<sup>2,4,5</sup>

### COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of congenital toxoplasmosis in a pediatric patient
- OR**
- The requested drug is being prescribed for the treatment of toxoplasmosis
- OR**
- The patient has an intolerance or contraindication to sulfamethoxazole/trimethoprim AND the requested drug is being prescribed for any of the following: A) Toxoplasmosis prophylaxis B) Pneumocystis jiroveci pneumonia prophylaxis C) Cystoisosporiasis

### REFERENCES

1. Daraprim [package insert]. New York, NY: Vyera Pharmaceuticals, LLC; August 2017.
2. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; [http://online.lexi.com/lco/action/index/dataset/complete\\_ashp](http://online.lexi.com/lco/action/index/dataset/complete_ashp) [available with subscription]. December 2017.
3. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. [www.micromedexsolutions.com](http://www.micromedexsolutions.com) [available with subscription]. December 2017.
4. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at [http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult\\_oi.pdf](http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf). Accessed December 2017.
5. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Available at [http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi\\_guidelines\\_pediatrics.pdf](http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf). Accessed December 2017.
6. Guidelines for the Treatment of Malaria in the United States. Centers for Disease Control and Prevention. Available at <https://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf>. Accessed December 2017.